Related Experiment Video
Updated: May 28, 2026
09:37
A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
The RANKL pathway and denosumab
1Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. rkdmail@sbglobal.net
Rheumatic Diseases Clinics of North America
|October 26, 2011
Summary
Denosumab (Prolia) is a biologic therapy for osteoporosis, targeting bone breakdown by inhibiting osteoclasts. It offers an effective treatment option for postmenopausal women, including those with kidney issues.
Area of Science:
- Pharmacology
- Bone Biology
- Immunology
Background:
- Osteoporosis is a significant health concern, particularly in postmenopausal women, increasing fracture risk.
- Osteoclast activity is a key driver of bone resorption in osteoporosis.
- Existing therapies have limitations, necessitating novel treatment approaches.
Purpose of the Study:
- To introduce Denosumab (Prolia) as a novel biologic therapy for postmenopausal osteoporosis.
- To highlight Denosumab's mechanism of action in inhibiting osteoclast function.
- To present Denosumab's efficacy and safety profile, including in patients with renal impairment.
Main Methods:
- Denosumab is a fully human monoclonal antibody targeting RANKL.
- It acts as an antiresorptive agent by interfering with osteoclast formation, activation, and survival.
- Administered as a 60-mg subcutaneous injection every six months.
Main Results:
- Denosumab effectively reduces bone resorption by inhibiting osteoclasts.
- Demonstrated efficacy and safety in treating postmenopausal osteoporosis.
- First biologic therapy for osteoporosis showing positive outcomes in patients with renal impairment.
Conclusions:
- Denosumab represents a significant advancement in osteoporosis treatment.
- Its targeted mechanism offers a new therapeutic strategy for bone health.
- Provides a valuable option for postmenopausal women at high fracture risk, including those with kidney compromise.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
01:41Non-Canonical Wnt Signaling Pathways
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...